Different types of cartilage neotissue fabricated from collagen hydrogels and mesenchymal stromal cells via SOX9, TGFβ1 or BMP2 gene transfer

Manuel Weißenberger1*, Manuela H. Weißenberger1, Mike Wagenbrenner1, Tizian Heinz1, Jenny Reboredo2, Boris M. Holzapfel1, Maximilian Rudert1, Jürgen Groll3, Christopher H. Evans4, Andre F. Steinert1

1 Department of Orthopaedic Surgery, König-Ludwig-Haus, Orthopaedic Center for Musculoskeletal Research (OCMR), Julius-Maximilians-University Würzburg, Würzburg, Germany, 2 Department of Tissue Engineering and Regenerative Medicine, Julius-Maximilians-University Würzburg, Würzburg, Germany, 3 Department of Functional Materials in Medicine and Dentistry, Julius-Maximilians-University Würzburg, Würzburg, Germany, 4 Department of Physical Medicine and Rehabilitation, Musculoskeletal Gene Therapy Research Laboratory, Mayo Clinic, Rochester, MN, United States of America

* Current address: Department of Orthopaedic, Trauma, Shoulder and Arthroplasty Surgery, Rhön-Klinikum, Campus Bad Neustadt, Bad Neustadt, Germany
m.weissenberger.klh@uni-wuerzburg.de

Abstract

Objective
As native cartilage consists of different phenotypical zones, this study aims to fabricate different types of neocartilage constructs from collagen hydrogels and human mesenchymal stromal cells (MSCs) genetically modified to express different chondrogenic factors.

Design
Human MSCs derived from bone-marrow of osteoarthritis (OA) hips were genetically modified using adenoviral vectors encoding sex-determining region Y-type high-mobility-box (SOX) 9, transforming growth factor beta (TGF) 1 or bone morphogenetic protein (BMP) 2 cDNA, placed in type I collagen hydrogels and maintained in serum-free chondrogenic media for three weeks. Control constructs contained unmodified MSCs or MSCs expressing GFP. The respective constructs were analyzed histologically, immunohistochemically, biochemically, and by qRT-PCR for chondrogenesis and hypertrophy.

Results
Chondrogenesis in MSCs was consistently and strongly induced in collagen I hydrogels by the transgenes SOX9, TGFβ1 and BMP2 as evidenced by positive staining for proteoglycans, chondroitin-4-sulfate (CS4) and collagen (COL) type II, increased levels of glycosaminoglycan (GAG) synthesis, and expression of mRNAs associated with chondrogenesis. The control groups were entirely non-chondrogenic. The levels of hypertrophy, as judged by expression of alkaline phosphatase (ALP) and COL X on both the protein and mRNA levels revealed different stages of hypertrophy within the chondrogenic groups (BMP2> TGFβ1> SOX9).
Conclusions
Different types of neocartilage with varying levels of hypertrophy could be generated from human MSCs in collagen hydrogels by transfer of genes encoding the chondrogenic factors SOX9, TGFβ1 and BMP2. This technology may be harnessed for regeneration of specific zones of native cartilage upon damage.

Introduction
Autologous chondrocyte transplantation (ACT) currently represents the standard of care for treating large, full-size chondral and osteochondral defects [1]. However, the application of ACT is limited, as it leads to donor site morbidity and yields only moderate cell numbers with limited differentiation capacities [2]. This is why mesenchymal stromal cells (MSCs) have appeared as a promising alternative for cell-based cartilage repair [3]. MSCs can be isolated from a variety of easily accessible tissues in high numbers and possess differentiation versatility, with bone-marrow being the most intensely investigated tissue source [4].

To develop a clinical application of MSC-based approaches for cartilage regeneration, a combination of MSCs with a beneficial 3D-microenvironment is necessary, containing an appropriate combination of biomaterials with differentiation factors [5]. Various biomaterials studied for this purpose comprise synthetic or natural polymers which prevent the loss of transplanted cells and simulate the natural structure of articular cartilage to promote chondrogenesis [5]. Among these, hydrogels retain large amounts of water, thereby imitating the highly hydrated extracellular matrix (ECM) in hyaline cartilage [6, 7]. Although natural hydrogels, like those formed by collagen fibers, lack stability, they include the benefits of high biocompatibility and biodegradability [6, 8, 9]. Especially collagen type I hydrogels are gaining popularity as scaffolds in cell-based cartilage repair due to their ready availability and safe use in vivo including several clinical trials [10–12].

Differentiation of MSCs toward a chondrogenic phenotype also requires specific stimulation which can include a great number of variables such as hypoxia, mechanical loading or the delivery of chondrogenic growth factors [9]. In this context, relatively little attention has been dedicated to the zonal organization of neocartilage tissue and how it depends upon the specific differentiation factor that is used. The most well studied soluble factors for chondrogenic induction of MSCs are the members of the transforming growth factor (TGF)-β family, such as TGF-β1 (encoded by TGFβ1) or bone morphogenetic protein (BMP)-2 (encoded by BMP2). Although, chondrogenic induction could be achieved using these factors under certain chondrogenic conditions in vitro [13], the problems with this approach include adequate delivery of these factors at sufficiently high and sustained concentrations in vivo and the high levels of hypertrophic chondrocytes which produce a matrix rich in type X collagen and express osteogenic marker genes.

To address issues surrounding the delivery and choice of chondrogenic factors, we [14, 15] and others [16, 17] have developed new approaches for delivering growth factors to MSCs to induce chondrogenic differentiation. In particular, the combination of gene transfer and biomaterials for cartilage tissue engineering has shown promising results (Table 1). In previous work using adenoviral gene transfer to MSCs we and others could show that marrow-derived MSCs were highly amenable to adenoviral transduction of TGFβ1 and BMP2 resulting in strong chondrogenic induction in pellet cultures in vitro [15] and cartilage defects in vivo [26]. However, the issue of chondrogenic hypertrophy in vitro and subsequent osteogenic induction within cartilage defects in vivo remains a problem.
Recently, the transcription factor sex-determining region Y-type high-mobility-group-box (SOX) 9 (encoded by SOX9) has been employed for chondrogenic induction of MSCs via gene delivery using adeno-associated virus (AAV) [16] or adenoviral vectors [30], which elicited significantly reduced levels of hypertrophy in pellet cultures in vitro. Because SOX9 is an intra-cellular protein, delivery by means other than gene transfer is difficult. The purpose of our current study was to combine the gene transfer of chondrogenic factors such as TGFβ1, BMP2 and SOX9 with a method of cell culture and delivery that has potential for in vivo application. Therefore, we used type I collagen hydrogels that are in clinical use rather than pellet culture and hypothesized that we could fabricate neo-cartilaginous tissues at different stages of cartilage hypertrophy depending upon the specific gene product encoded by the transferred cDNAs.

### Materials and methods

#### Generation and propagation of recombinant adenoviral vectors

Adenoviral vectors carrying green fluorescent protein (GFP) from jellyfish, the transcription factor SOX9 with a GFP fusion construct, TGFβ1 and BMP2 cDNA were generated by cre-lox recombination, amplified, purified and used as described before [31–33]. The resulting vectors were termed Ad.GFP, Ad.SOX9, Ad.TGFβ1 and Ad.BMP2. The preparation of recombinant adenovirus suspensions was carried out by amplification in 293 cells followed by purification using three consecutive CsCl gradients. Virus stock titers were estimated by optical density at 260 nm and standard plaque assay, and ranged between 10^{12}–10^{13} particles/mL.
Culture and transduction of human marrow-derived MSCs

After approval of the institutional review board of the Julius-Maximilians-University Würzburg and informed consent of all patients, MSCs were isolated from the femoral head of five patients undergoing total hip arthroplasty due to primary osteoarthritis using a protocol described earlier [33, 34]. Briefly, the collected cells were spun, re-suspended and plated at 2–3 $\times 10^8$ nucleated cells per 150 cm$^2$ flask (Falcon, Beckton Dickinson Labware, Franklin Lakes, NJ) using complete DME/F-12 medium (DMEM) containing 10% FBS and 1% penicillin/streptomycin, 1 ng/mL FGF-2 (all Invitrogen GmbH, Darmstadt, Germany). After 3 days, unattached cells were removed, and adherent cells were cultured at 37˚C in a humidified atmosphere of 95% air and 5% CO$_2$ in DMEM. Medium changes were performed every 3–4 days. As soon as cells reached confluency (approximately 1.2 $\times 10^6$ cells/150 cm$^2$ flask), the cultures were washed with phosphate buffered saline (PBS) and infected in 750 $\mu$L serum-free DMEM for 2 hours at a dose of 5 $\times 10^2$ infectious particles/cell of Ad.GFP (control group), Ad.SOX9, Ad.TGFBI or Ad.BMP2, or remained uninfected. The supernatant was removed after 2 hours of viral infection and replaced with DMEM.

Fabrication and culture of collagen hydrogel constructs

The type I collagen hydrogel was derived from collagen fibers isolated from rat tails (8–10 weeks old, both sexes) as described previously [13]. After washing the collagen fibres with PBS and sterilizing them with 70% EtOH, they were dissolved in acetic acid (0.1%) at a concentration of 6 mg/mL. To obtain a collagen matrix, the gel was mixed with a gel neutralization solution (GNL), that contained DMEM, FCS, and HEPES buffer. Following neutralization, 3 $\times 10^5$ cells were suspended in 0.15 mL GNL and transduced at 5 $\times 10^2$ infectious particles (ip)/cell for each vector with non-transduced or marker gene (GFP) transduced cultures as controls. Thereafter, 0.15 mL type I collagen hydrogel was added and mixed carefully in order to avoid air inclusion. Then 1 mL of the mixture was pipetted into a polypropylene, v-bottom 96-well plate (Corning, Corning, NY, USA). Gel polymerization was allowed in a 5% humidified atmosphere at 37˚C for 30 min. Then 0.1 mL of a defined cell culture medium (serum-free DMEM containing 1 mM pyruvate, 1% ITS + Premix, 37.5 mg/ml ascorbate-2-phosphate and 10$^{-7}$ M dexamethasone (all Sigma, St. Louis, MO, USA) was added to each well for overnight incubation. The next day the gels were put in a 24-well plate (Corning, Corning, NY, USA) and cultured with 2 mL medium which was changed every 2–3 days until harvesting.

Assessment of transgene expression

Transgene expression for the marker gene GFP and the chondrogenic factor SOX9, which is fused to GFP in this construct, was measured by fluorescence microscopy, whereas TGFBI and BMP2 expression were measured with commercially available ELISA kits as directed by the supplier (R&D Systems) and 24 hour-conditioned media collected at days 3, 7, 14 and 21.

Biochemical assays

For assessment of cell proliferation, glycosaminoglycan (GAG) synthesis and alkaline phosphatase (ALP; encoded by ALPL) activity biochemical assays were performed as described earlier [33]. Briefly, for detection of cell proliferation a quantitative adenosine 5’-triphosphate (ATP) assay was performed using the CellTiter-Glo® Luminescent Cell Viability Assay (Promega). After papain digestion (1 $\mu$g/mL, Sigma), synthesis of GAG was evaluated by reaction with 1,9-dimethylmethylene blue (DMMB) using the Blyscan™ Sulfated Glycosaminoglycan Assay (Biocolor Ltd., Newtownabbey, Northern Ireland). For detection of ALP activity, a kit
(Sigma) was used that measured ALP activity based upon the conversion of p-nitrophenyl phosphate to p-nitrophenol and inorganic phosphate; absorbance at 405 nm was measured in an ELISA plate reader. Using the Quant-iT™ PicoGreen® kit (Invitrogen), the GAG content and the ALP activity were normalized to DNA content.

**Histology and immunohistochemistry**

Type I collagen hydrogel aggregates were fixed at day 21 in 4% paraformaldehyde, followed by dehydration, paraffin embedding, sectioning and staining with hematoxylin/eosin (H&E), alcian blue and ALP (all Sigma) according to previously published protocols [33]. Alternate sections were used for immunohistochemistry. The following antibody treatments were used: type II collagen (COL II) (pepsin (1 mg/ml; Sigma)/monoclonal anti-COL II antibodies (Acris Antibodies GmbH, Hiddenhausen, Germany)); chondroitin-4-sulfate (CS4) (chondroitinase ABC (5 U/mL; Sigma)/monoclonal anti-CS4 antibodies (Millipore GmbH, Schwalbach, Germany)); type X collagen (COL X) (0.25% trypsin; Sigma)/polyclonal anti-COL X antibodies (Calbiochem, Bad Soden, Germany). Visualization of the immunostainings was performed by treatment with Advance™ HRP link and Advance™ HRP enzyme (Dako, Hamburg, Germany) followed by diaminobenzidine staining (DAB kit; Sigma). Thereafter, the slides were counterstained with hemalaun (Merck, Darmstadt, Germany). Controls with non-immune IgG (Sigma) were performed for all immunohistochemical analyzes.

**RNA extraction and reverse-transcription quantitative PCR analyzes**

RNA was extracted from the hydrogel constructs at days 3, 7, 14 and 21, and 2 μg RNA from each group used for reverse transcription using random hexamer primers (Table 2) and BioScript reverse transcriptase (Bioline GmbH, Luckenwalde, Germany). Quantitative PCR (qPCR) was performed in triplicate with 1 μL cDNA, 10 μL KAPA SYBR FAST Universal 2x qPCR Master Mix (peqlab Biotechnologie GmbH) and 1 μL of gene specific primers. Eventually, qPCR was performed with Opticon DNA Engine (MJ Research, Waltham, USA) under the following conditions: 95°C for 3 min; 40 cycles: 95°C for 15 s; 58°C for 20 s; 72°C for 30 s; thereafter the melting curve was analyzed. Final results were calculated using the ΔΔC_T method.

| Gene | RT-PCR primer sequences (5’-3’) | Annealing temp. (°C) | Product size (bp) | Cycles |
|------|---------------------------------|---------------------|------------------|--------|
| **Chondrogenic markers** | | | | |
| COL2A1 | Sense: TTTCAGGCTCAAGATGGTC | 58 | 374 | 35 |
| | Antisense: ATCTGAAGAAGGAGACGAG | | | |
| SOX9 | Sense: ATCTGAAGAAGGAGACGAG | 58 | 263 | 35 |
| | Antisense: TCAGAAGTCTCCAGAGCTTG | | | |
| **Hypertrophy and osteogenic markers** | | | | |
| COL10A1 | Sense: CCGTTTTGCTGCTAGTATCC | 54 | 468 | 25 |
| | Antisense: CTGTTTGCCAGGGTTTCCTGGCAC | | | |
| ALPL | Sense: TGGAGCTTCAGAAAGCTCAACACCA | 51 | 454 | 35 |
| | Antisense: TCAGTTTGCTCGAGTACCAGTCC | | | |
| **Internal control** | | | | |
| EF-1α | Sense: AGGTTGATTATCCCTGAACCATCC | 54 | 234 | 25 |
| | Antisense: AAAGGTGATAGTCTCGAAGGAC | | | |
Statistical analyzes

Numeric data from the ELISA, ATP, GAG, DNA, and ALP analyzes were expressed as mean values, range and standard deviation (SD), with each experiment being performed in triplicate or quadruplicate (n = 3–4), and repeated on at least 3–5 individual marrow preparations from different patients (n = 3–5), as indicated in the respective experiments. Numeric data were subjected to variance analysis (one or two factor ANOVA) and statistical significance between the different groups and timepoints was determined by the Friedman-Test and the Kruskal Wallis-Test with p < 0.05 being considered significant.

Results

Transgene expression by genetically-modified MSCs in collagen hydrogel constructs

MSCs modified with adenoviral vectors encoding GFP (control), SOX9, TGFβ1 or BMP2 and contained in type I collagen hydrogel constructs expressed high levels of the respective transgenes at day 3 of culture. The transgene expression in the negative control group GFP and transgene group SOX9 measured by fluorescence microscopy showed high levels at day 3, decreasing progressively at later time points (Fig 1A and 1B). Concentrations of 11 to 13 ng/mL of TGF-β1 (Fig 1C) or 12 to 14 ng/mL BMP-2 (Fig 1D) were measured, with declining values during the three weeks time-course. In the marker gene controls, the amount of each growth factor transgene was persistently low (< 0.01 ng/mL).

![Fig 1](https://doi.org/10.1371/journal.pone.0237479.g001)

Fig 1. Transgene expression by MSCs in hydrogels during 21 days of culture following adenoviral gene transfer of GFP, SOX9, TGFβ1 or BMP2. Primary MSCs were transduced with Ad.GFP, Ad.SOX9, Ad.TGFβ1 or Ad.BMP2 at 5 x 10^2 vp/cell for each vector, seeded into type I collagen hydrogels and analyzed for the respective transgene expression during 21 days. Expression of the GFP transgene was analyzed by fluorescence microscopy in the hydrogels modified with Ad.GFP (a) or Ad. SOX9/GFP (b). Expression of the TGFβ1 (c) and BMP-2 (d) transgenes was measured by ELISA. The data represent mean values ± SD from measurements of supernatants of n = 3 hydrogel aggregates per condition and time point; m = 3 marrow preparations were analyzed. Each experiment was performed in triplicate. Statistically different values from GFP+ control hydrogels are marked by asterisks (p < 0.05).
H&E
Day 21

(a) GFP

(b) SOX9

(c) TGFβ1

(d) BMP2
Histological and immunohistochemical analyzes of chondrogenic differentiation

The degree of cellularity of the respective hydrogels containing MSCs transduced with Ad. GFP, Ad.SOX9, Ad.TGFβ1 and Ad.BMP2 after 21 days in culture is shown by H & E staining of representative hydrogel constructs in Fig 2. After 21 days of culture the Ad.GFP (Fig 2A) hydrogel constructs showed a higher degree of cellularity compared to Ad.SOX9 (Fig 2B) and Ad.BMP2 (Fig 2D) hydrogel constructs. The Ad.TGFβ1 (Fig 2C) hydrogels showed the lowest degree of cellularity with loose complexes of cells surrounded by vast amounts of extracellular matrix. Alcian blue staining (Fig 3) revealed strong metachromatic staining for proteoglycans in the extracellular matrix deposited by the Ad.SOX9, Ad.TGFβ1 and Ad.BMP2 (Fig 3B–3D) transfected MSCs in type I collagen hydrogel constructs, in comparison to the Ad.GFP (Fig 3A) transfected control group.

Accordingly, immunohistochemical stainings for CS4 (Fig 4), part of the polysaccharide fractions of cartilage GAGs, showed increased production by MSCs at day 21 of culture in the Ad.SOX9, Ad.TGFβ1 and Ad.BMP2 (Fig 4B–4D) hydrogel constructs in comparison to the Ad.GFP controls (Fig 4A) which showed only very low levels of staining for CS4.

Similar results were observed in the immunohistochemical stainings for COL II (Fig 5), the main cartilage matrix protein, which proved increased production of the molecule by MSCs at day 21 of culture in the Ad.SOX9, Ad.TGFβ1 and Ad.BMP2 (Fig 5B–5D) hydrogel constructs in comparison to the Ad.GFP (Fig 5A) controls which low levels of COL II staining. Distinct differences in the expression levels of all mentioned chondrogenic markers between the SOX9, TGFβ1 and BMP2 transduced hydrogel constructs were not evident.

Immunohistochemical analyzes of chondrogenic hypertrophy

Chondrocyte hypertrophy was assessed by immunohistochemical analyzes for COL X (Fig 6) and ALP (Fig 7). The control group Ad.GFP showed only limited immunostaining of COL X at day 21 (Fig 6A). Similarly, only weak COL X staining could be seen in the hydrogel constructs containing chondrogenic differentiated MSCs transduced with Ad.SOX9 (Fig 6B). In contrast, after 21 days intense COL X staining could be observed in the Ad.TGFβ1 and Ad. BMP2 hydrogel constructs (Fig 6C and 6D).

Correspondingly, no or only very weak staining for ALP was detected in the type I collagen hydrogels containing MSCs transduced with Ad.GFP which served as a control group (Fig 7A), as well as in the hydrogels containing MSCs modified with Ad.SOX9 (Fig 7B). In contrast, hydrogels containing MSCs that were transduced with Ad.TGFβ1 and Ad.BMP2 showed increased staining for ALP, in particular in the extracellular matrix of the outer rim of the aggregates (Fig 7C and 7D).

Biochemical assays for cell proliferation, DNA and GAG Content, and ALP activity

After 21 days of culture in type I collagen hydrogels we performed ATP cell proliferation assays to estimate changes of cell viability in MSCs after adenoviral transduction with Ad.GFP, Ad. SOX9, Ad.TGFβ1 and Ad.BMP2 (Fig 8A). High rates of cell proliferation were observed in all
Alcian blue
Day 21

(a) GFP

(b) SOX9

(c) TGFβ1

(d) BMP2
groups with highest values for the Ad.BMP2 transduced group without major differences between the other groups (Fig 8A). The same pattern was seen in the DNA assay, where high values were observed in all groups without major differences between the Ad.GFP transduced control and the other groups (Fig 8B).

The extracellular matrix produced by chondrocytes in hyaline cartilage contains vast amounts of GAGs. Therefore, the GAG assay was performed to compare quantitative synthesis of extracellular matrix components characteristic for hyaline cartilage among the differently treated groups of MSCs in type I collagen hydrogels (Fig 8C). The hydrogels containing MSCs transduced with Ad.SOX9, Ad.TGFβ1 and Ad.BMP2 showed significantly elevated levels of GAG synthesis in comparison to the MSCs from the non-chondrogenic Ad.GFP control group (Fig 8C).

For evaluation of chondrogenic hypertrophy we analyzed ALP activity within the different hydrogels. This was found to be markedly increased at time points 7, 14 and 21 in the Ad.BMP2 transduced group and at day 21 in the Ad.TGFβ1 transduced MSC-hydrogels with no increase in the Ad.GFP and Ad.SOX9 transduced MSC-hydrogels (Fig 8D).

RT-qPCR analyzes of chondrogenic and hypertrophy marker gene expression

The temporal expression profiles of chondrogenic and osteogenic differentiation markers following gene delivery of the factors GFP, SOX9, TGFβ1 and BMP2 were analyzed by quantitative real-time RT-PCR (Fig 9, Table 2). For the assessment of chondrogenic maturation the marker genes SOX9 and COL II alpha 1 (COL2A1) were included, whereas possible hypertrophic differentiation was examined using the marker genes COL X alpha 1 (COL10A1) and ALPL.

At days 14 and 21 SOX9 and COL2A1 were significantly upregulated in the transgene groups SOX9, TGFβ1 and BMP2 compared to the negative control group GFP (Fig 9). Evidence of chondrocyte hypertrophy, signaled by an increase in COL10A1 mRNA expression, was seen in MSC-hydrogels modified with TGFβ1 or BMP2 at day 21 (Fig 9). Furthermore we found an up-regulation of the hypertrophic marker gene ALPL at days 14 and 21 in the Ad.TGFβ1 and Ad.BMP2 transduced MSCs (Fig 9). In contrast, these hypertrophic mRNAs were very low or even undetectable in the Ad.GFP and Ad.SOX9 transduced MSCs contained in type I collagen hydrogels.

Discussion

The triad of CTE consists of cells, whose differentiation is initiated and maintained by specific growth factors and which are delivered to their target site through adequate biomaterials [35]. In recent years all three contributing factors have been subject to extensive research, revealing a series of obstacles which have to be overcome in order to enable a general clinical use in cartilage regeneration [2, 35]. Among these hurdles are chondrogenic hypertrophy, the search for effective delivery methods of chondrogenic growth factors in vivo as well as for biomaterials with potential use for in vivo application [2, 36].
Chondroitin-4-sulfate

Day 21

(a) GFP

(b) SOX9

(c) TGFβ1

(d) BMP2
We and other researchers previously examined the use of gene therapy as a possibility to enable an autonomous, long-lasting production of chondrogenic growth factors by MSCs [14, 16, 30]. The single or combined adenoviral gene transfer of TGFβ1 and BMP2 promoted chondrogenic differentiation in MSCs when using pellet culture [15]. Later we and others found that the gene transfer of SOX9 not only led to chondrogenic differentiation in MSCs but also reduced chondrogenic hypertrophy in comparison to delivery of TGFβ1 or BMP2 [23, 30].

In our present in vitro study we transferred our earlier findings from pellet culture to the use of type I collagen hydrogels which have shown great potential for in vivo application in CTE [9, 12, 13]. Histological, immunohistochemical and molecularbiological results showed that adenoviral transfer of cDNAs encoding Ad.TGFβ1, Ad.BMP2 or Ad.SOX9 led to successful chondrogenic differentiation in MSCs after three weeks of culture in type I collagen hydrogels. In comparison to the transfer of SOX9 and BMP2, the transduction with TGFβ1 led to a significant higher expression of COL2A1. The gene transfer of BMP2 more than TGFβ1 also induced a significant upregulation of the hypertrophy marker gene ALP and positive immunostainings for COL X and ALP. While adenoviral transfer of SOX9 still led to clear chondrogenesis in MSCs, levels of chondrogenic hypertrophy after 21 days of culture in type I collagen hydrogels were significantly lower as shown by ALP activity, immunostainings and qPCR.

Hence, adenoviral transfer of Ad.TGFβ1, Ad.BMP2 or Ad.SOX9 led to chondrogenic differentiation but also different levels of chondrogenic hypertrophy in MSCs. This proved that our earlier findings regarding the different effects of gene transfer of TGFβ1 and SOX9 to MSCs could not only be observed when using pellet cultures but also when culturing MSCs in type I collagen hydrogels which are already in clinical use for CTE [30]. This technology may be used to overcome the search for effective delivery methods of cells and chondrogenic growth factors in vivo while offering possibilities to regenerate specific zones of native cartilage upon damage.

Earlier Nöth et al. showed that the combination of type I collagen hydrogels with soluble growth factors such as rhTGF-β1 and rhBMP-2 successfully induced and maintained chondrogenesis in MSCs in vitro [13]. When comparing the effects of TGF-β1 with BMP-2, the synthesis of cartilage-specific matrix proteins and the upregulation of chondrogenic marker genes appeared to set in earlier and to be stronger in TGF-β1 treated cultures. Interestingly, both groups also showed signs of hypertrophy after 21 days, with the upregulation of marker genes and proteins specific for hypertrophy setting in earlier in cultures treated with TGF-β1 which is in line with our data [13]. Jiang et al. showed that genetic silencing of SOX9 prevented chondrogenic differentiation in MSCs when cultured in type I collagen hydrogels in a medium containing TGF-β1 [37]. In contrast, gene transfer of SOX9 to MSCs led to improved chondrogenic differentiation in vitro while suppressing hypertrophy and osteogenic differentiation when cultured in pellet-aggregates or fibrin-polyurethane scaffolds [23, 24]. This is in accordance to our findings in which adenoviral gene transfer of SOX9 to MSCs led to clear chondrogenesis in MSCs when cultured in type I collagen hydrogels for 21 days. In contrast to our findings Kupcsik et al. only observed GAG synthesis in MSCs cultured in hydrogels only when combining gene transfer of SOX9 with mechanical stimulation [38].

We used type I collagen hydrogels to examine the effects of gene transfer on chondrogenesis in MSCs in combination with clinically approved biomaterials [10, 11]. Natural scaffolds, like the type I collagen hydrogel, are attractive for their great biocompatibility and biodegradability.
Fig 5. Immunohistochemical analyzes for type II collagen in MSC hydrogels after chondrogenic differentiation by adenoviral gene transfer of SOX9, TGFβ1 or BMP2. MSCs in monolayer cultures were infected with Ad.GFP (Control; a), Ad.SOX9 (b), Ad.TGFβ1 (c) or Ad.BMP2 (d) at 5 x 10^2 vp/cell for each vector as indicated, seeded into hydrogel aggregates 24 h post infection and cultured in serum-free medium for 21 days. Immunohistochemical staining for type II collagen (COL II), the predominant collagen in hyaline cartilage, was performed on representative sections after 21 days. (a-d) Panels are shown at low (50x; bar = 200 μm) or high (200x; bar = 50 μm) magnification as indicated, and regions of positive immunostaining appear brown.

https://doi.org/10.1371/journal.pone.0237479.g005
Fig 6. Immunohistochemical analyzes for type X collagen in MSC hydrogels after chondrogenic differentiation by adenoviral gene transfer of SOX9, TGFβ1 or BMP2. MSCs in monolayer cultures were infected with Ad.GFP (Control; a), Ad.SOX9 (b), Ad.TGFβ1 (c) or Ad.BMP2 (d) at 5 × 10^2 vp/cell for each vector as indicated, seeded into hydrogel aggregates 24 h post infection and cultured in serum-free.
medium for 21 days. Immunohistochemical staining for type X collagen (COL X) was performed on representative sections after 21 days. (a-d) Panels are shown at low (50x; bar = 200 μm) or high (200x; bar = 50 μm) magnification as indicated; regions of positive immunostaining appear brown.

https://doi.org/10.1371/journal.pone.0237479.g006

Alkaline phosphatase
Day 21

(a) GFP

(b) SOX-9

(c) TGF-β1

(d) BMP-2

Fig 7. Histochemical analyzes for alkaline phosphatase in MSCs hydrogels after chondrogenic differentiation by adenoviral gene transfer of SOX9, TGFb1 or BMP2. MSCs in monolayer cultures were infected with Ad.GFP (Control; a), Ad.SOX9 (b), Ad.TGFb1 (c) or Ad.BMP2 (d) at 5 x 10^2 vp/cell for each vector as indicated, seeded into hydrogel aggregates 24 hours post infection and cultured in serum-free medium for 21 days. Histochemical staining for alkaline phosphatase (ALP) was performed on representative sections after 21 days. (a-d) Panels are shown at low (50x; bar = 200 μm) or high (200x; bar = 50 μm) magnification as indicated, and regions of positive staining appear blue.

https://doi.org/10.1371/journal.pone.0237479.g007
through natural enzymes such as collagenase, which would ideally occur at the same speed as neo-cartilage is rebuilt [36]. In addition, scaffolds formed by collagen interact with seeded MSCs and local cells promoting cellular interactions, cellular signaling and production of cartilage-specific matrix proteins [9]. Besides promoting the synthesis of a hyaline cartilage-specific ECM these natural materials have also been shown to maintain the phenotype of chondrocytes in vitro [39, 40]. Because hydrogels are highly hydrated, they partly reproduce the natural environment of the ECM in hyaline cartilage [6]. Interestingly, type II collagen scaffolds blended with chondroitin led to a greater deposition of cartilage-specific matrix proteins and preservation of chondrogenic phenotype than type I collagen scaffolds seeded with chondrocytes [9]. Despite these findings one major disadvantage counteracting the benefits of natural type II collagen hydrogels are possibly pro-arthritogenic effects in vivo that significantly restrict their possible clinical use, which is why we used type I collagen hydrogels in this study [41].

The combination of natural or synthetic biomaterials with gene transfer of chondrogenic growth factors to MSCs has already produced promising results in a number of animal in vivo studies [42]. The adenoviral transfer of SOX9 to MSCs which were seeded in polyglycolic acid scaffolds significantly improved the repair of full-thickness cartilage defects in rabbits [22]. Further the transduction of MSCs with TGFBI led to improved repair of full-thickness cartilage defects in rats when seeded in polyglycolic acid scaffolds [43].
When regarding the future use of biomaterials for CTE the additional or single use of other components such as biotechnological chondroitin or hyaluronic acid could provide different benefits for the chondrogenic differentiation of MSCs while synthetic polymers allow modifications of structural and surface conditions [42, 44, 45]. In addition, bi- or multiphasic scaffolds may allow a better simulation of the osteochondral interface and the complex structure of hyaline cartilage to further improve the formation of different stages of chondrogenesis in seeded cells [46, 47]. Finally, safe ways of delivering the factors we investigated are necessary that meet regulatory guidelines, before such promising approaches can be advanced to clinical application.

Conclusion

The combination of adeno viral gene transfer of either TGFB1, BMP2 or SOX9 to MSCs with in vitro culture in type I collagen hydrogel constructs led to successful chondrogenesis after 21 days. Our data suggests that TGFB1 and BMP2 rather than SOX9 induced a significant hypertrophic response in bone-marrow MSCs seeded in type I collagen hydrogels, resulting in different types of neo-cartilaginous tissues. This technology might be used to regenerate the zonal architecture of hyaline cartilage in vivo. However, to further examine and optimize the effect of gene transfer of SOX9, TGFB1 or BMP2 to MSCs for CTE, safe ways of delivery have to be
explored in conjunction with confirmation in meaningful in vivo studies, before this research can be advanced to clinical application.

**Supporting information**

S1 Fig. SOX9-Transgen. (JPG)

S2 Fig. GFP-Transgen. (JPG)

S1 Data. qRT-PCR. (XLSX)

S2 Data. TGFb1-ELISA. (XLSX)

S3 Data. BMP2-ELISA. (XLSX)

S4 Data. ALP-Assay. (XLSX)

S5 Data. DNA-Assay. (XLSX)

S6 Data. GAG-Assay. (XLSX)

S7 Data. ATP-Assay. (XLSX)

**Author Contributions**

**Conceptualization:** Manuel Weißenberger, Andre F. Steinert.

**Data curation:** Manuel Weißenberger, Manuela H. Weißenberger, Jenny Reboredo.

**Formal analysis:** Manuel Weißenberger, Manuela H. Weißenberger.

**Funding acquisition:** Manuel Weißenberger, Jürgen Groll, Andre F. Steinert.

**Investigation:** Manuel Weißenberger, Jenny Reboredo, Andre F. Steinert.

**Methodology:** Manuel Weißenberger, Manuela H. Weißenberger, Jenny Reboredo.

**Project administration:** Manuel Weißenberger, Mike Wagenbrenner, Andre F. Steinert.

**Resources:** Manuel Weißenberger, Boris M. Holzapfel, Maximilian Rudert, Jürgen Groll, Andre F. Steinert.

**Software:** Manuel Weißenberger, Tizian Heinz, Jürgen Groll.

**Supervision:** Manuel Weißenberger, Manuela H. Weißenberger, Boris M. Holzapfel, Maximilian Rudert, Andre F. Steinert.

**Validation:** Manuel Weißenberger, Manuela H. Weißenberger, Boris M. Holzapfel, Christopher H. Evans, Andre F. Steinert.

**Visualization:** Manuel Weißenberger.
Writing – original draft: Manuel Weißenberger, Mike Wagenbrenner, Boris M. Holzapfel, Maximilian Rudert, Christopher H. Evans, Andre F. Steinert.

Writing – review & editing: Manuel Weißenberger, Mike Wagenbrenner, Tizian Heinz, Boris M. Holzapfel, Maximilian Rudert, Jürgen Groll, Christopher H. Evans, Andre F. Steinert.

References

1. Schenker H, Wild M, Rath B, et al. [Current overview of cartilage regeneration procedures]. Der Orthopäde. 2017; 46(11):907–913. https://doi.org/10.1007/s00132-017-3474-7 PMID: 28980022

2. Steinert AF, Ghivizzani SC, Rethwilm A, Tuan RS, Evans CH, Noth U. Major biological obstacles for persistent cell-based regeneration of articular cartilage. Arthritis Res Ther. 2007; 9(3):213. https://doi.org/10.1186/ar1986

3. Friedenstei AJ, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. Cell and tissue kinetics. 1987; 20(3):263–272. https://doi.org/10.1111/j.1365-2184.1987.tb01309.x PMID: 3690262

4. Vecchione MC, Torno DA, Mastrogiacomo E, et al. Use of autologous bone marrow mononuclear cells by means of a new scaffold in the treatment of full-thickness articular cartilage defects. Clin Orthop Relat Res. 2007; 465:19–26. https://doi.org/10.1097/01.blo.0000261769.67820.91

5. Gugjoo MB, Sharma GT, Aithal HP, Kinjavdekar P. Cartilage tissue engineering: Role of mesenchymal cells and growth factors. Journal of biomaterials research Part A. 2012; 100(10):2717–2726. https://doi.org/10.1002/jbm.a.34194 PMID: 22923365

6. Irawan V, Sung TC, Higuchi A, Ikoma T. Collagen Scaffolds in Cartilage Tissue Engineering and Relevant Approaches for Future Development. Tissue engineering and regenerative medicine. 2018; 15(5):673–689. https://doi.org/10.1177/1377018418819120 PMID: 29025088

7. Zhou X, Zhang W, Yang M. Application of Hydrogels in Cartilage Tissue Engineering. Current stem cell research & therapy. 2018; 13(7):497–516.

8. Zhang L, Yuan T, Guo L, Zhang X. An in vitro study of collagen hydrogel to induce the chondrogenic differentiation of mesenchymal stem cells. Journal of biomedical materials research Part A. 2012; 100(10):2717–2726. https://doi.org/10.1002/jbm.a.34194 PMID: 22923365

9. Irawan V, Sung TC, Higuchi A, Ikoma T. Collagen Scaffolds in Cartilage Tissue Engineering and Relevant Approaches for Future Development. Tissue engineering and regenerative medicine. 2018; 15(5):673–689. https://doi.org/10.1177/1377018418819120 PMID: 29025088

10. Schneider U, Rackwitz L, Andereya S, et al. A prospective multicenter study on the outcome of type I collagen hydrogel-based autologous chondrocyte implantation (CaReS) for the repair of articular cartilage defects in the knee. The American journal of sports medicine. 2011; 39(12):2558–2565. https://doi.org/10.1177/0363546511423369 PMID: 21984690

11. Kuroda R, Ishida K, Matsumoto T, et al. Treatment of a full-thickness articular cartilage defect in the femoral condyle of an athlete with autologous bone-marrow stromal cells. Osteoarthritis Cartilage. 2007; 15(2):226–231. https://doi.org/10.1016/j.joca.2006.08.008 PMID: 17002893

12. Huang BJ, Hu JC, Athanasiou KA. Cell-based tissue engineering strategies used in the clinical repair of articular cartilage. Biomaterials. 2016; 98:1–22. https://doi.org/10.1016/j.biomaterials.2016.04.018 PMID: 27177218

13. Noth U, Rackwitz L, Heymer A, et al. Chondrogenic differentiation of human mesenchymal stem cells in collagen type I hydrogels. Journal of biomedical materials research Part A. 2007; 83(3):626–635. https://doi.org/10.1002/jbm.a.31254 PMID: 17503531

14. Steinert AF, Noth U, Tuan RS. Concepts in gene therapy for cartilage repair. Injury. 2008; 39 Suppl 1: S97–113.

15. Steinert AF, Palmer GD, Pilapil C, Noth U, Evans CH, Ghivizzani SC. Enhanced in vitro chondrogenesis of primary mesenchymal stem cells by combined gene transfer. Tissue Eng Part A. 2009; 15(5):1127–1139. https://doi.org/10.1089/teng.2007.0252 PMID: 18826340

16. Evans CH, Ghivizzani SC, Smith P, Shuler FD, Mi Z, Robbins PD. Using gene therapy to protect and restore cartilage. Clin Orthop Relat Res. 2000(379 Suppl):S214–219. https://doi.org/10.1097/00003086-20001001-00027 PMID: 11039771

17. Trippel SB, Ghivizzani SC, Nixon AJ. Gene-based approaches for the repair of articular cartilage. Gene Ther. 2007; 11(4):351–359. https://doi.org/10.1038/sj.gt.3302201 PMID: 14724680

18. Li WJ, Tuli R, Okafor C, et al. A three-dimensional nanofibrous scaffold for cartilage tissue engineering using human mesenchymal stem cells. Biomaterials. 2005; 26(6):599–609. https://doi.org/10.1016/j.biomaterials.2004.03.005 PMID: 15282138
19. Xia W, Jin YQ, Kretlow JD, et al. Adenoviral transduction of hTGF-beta1 enhances the chondrogenesis of bone marrow derived stromal cells. *Biotecnology letters.* 2009; 31(5):639–646. https://doi.org/10.1007/s10529-009-9930-7 PMID: 19169885

20. Wang X, Li Y, Han R, et al. Demineralized bone matrix combined bone marrow mesenchymal stem cells, bone morphogenetic protein-2 and transforming growth factor-beta3 gene promoted pig cartilage defect repair. *PloS one.* 2014; 9(12):e116061. https://doi.org/10.1371/journal.pone.0116061 PMID: 25545777

21. Leng P, Ding CR, Zhang HN, Wang YZ. Reconstruct large osteochondral defects of the knee with hLGf-1 gene enhanced Mosaicplasty. *The Knee.* 2012; 19(6):804–811. https://doi.org/10.1016/j.knee.2012.03.009 PMID: 22483989

22. Cao L, Yang F, Liu G, et al. The promotion of cartilage defect repair using adenovirus mediated Sox9 gene transfer of rabbit bone marrow mesenchymal stem cells. *Biomaterials.* 2011; 32(16):3910–3920. https://doi.org/10.1016/j.biomaterials.2011.02.014 PMID: 21377725

23. Venkatesan JK, Ekici M, Madhy R, Schmitt G, Kohn D, Cucchiariini M, SOX9 gene transfer via stable, replication-defective recombinant adeno-associated virus vectors as a novel, powerful tool to enhance the chondrogenic potential of human mesenchymal stem cells. *Stem Cell Res Ther.* 2012; 3(3):22. https://doi.org/10.1186/scrt113 PMID: 22742415

24. Venkatesan JK, Gardner O, Rey-Rico A, et al. Improved Chondrogenic Differentiation of rAAV SOX9-Modified Human MSCs Seeded in Fibrin-Polyurethane Scaffolds in a Hydrodynamic Environment. *Int J Mol Sci.* 2018; 19(9).

25. Lu CH, Yeh TS, Yeh CL, et al. Regenerating cartilages by engineered ASCs: prolonged TGF-beta3/BMP-6 expression improved articular cartilage formation and restored zonal structure. *Molecular therapy: the journal of the American Society of Gene Therapy.* 2014; 22(1):186–195.

26. Lee JM, Im GI. SOX trio-co-transduced adipose stem cells in fibrin gel to enhance cartilage repair and delay the progression of osteoarthritis in the rat. *Biomaterials.* 2012; 33(7):2016–2024. https://doi.org/10.1016/j.biomaterials.2011.11.050 PMID: 22189147

27. Goodrich LR, Hidaka C, Robbins PD, Evans CH, Nixon AJ. Genetic modification of chondrocytes with insulin-like growth factor-1 enhances cartilage healing in an equine model. *The Journal of bone and joint surgery British volume.* 2007; 89(5):672–685. https://doi.org/10.1002/jb.895 PMID: 17540757

28. Kaul G, Cucchiariini M, Arntzen D, et al. Local stimulation of articular cartilage repair by transplantation of encapsulated chondrocytes overexpressing human fibroblast growth factor 2 (FGF-2) in vivo. *J Gene Med.* 2006; 8(1):100–111. https://doi.org/10.1002/jgm.819 PMID: 16097039

29. Orth P, Kaul G, Cucchiariini M, et al. Transplanted articular chondrocytes co-overexpressing IGF-I and FGF-2 stimulate cartilage repair in vivo. *Knee surgery, sports traumatology, arthroscopy: official journal of the ESSKA.* 2011; 19(12):2119–2130.

30. Weissenger M, Weissenger MH, Gilbert F, Groß J, Evans CH, Steinert AF. Reduced hypertrophy in vitro after chondrogenic differentiation of adult human mesenchymal stem cells following adenoviral SOX9 gene delivery. *BMC musculoskeletal disorders.* 2020; 21(1):109. https://doi.org/10.1186/s12891-020-3137-4 PMID: 32066427

31. Hardy S, Kitamura M, Harris-Stansil T, Dai Y, Phipps ML. Construction of adenovirus vectors through Cre-lox recombinat ion. *Journal of virology.* 1997; 71(3):1842–1849. https://doi.org/10.1128/JVI.71.3.1842-1849.1997 PMID: 9032314

32. Palmer G, Gouze E, Gouze JN, Betz O, Evans CH, Ghivizzani SC. Gene transfer to articular chondrocytes with recombinant adenovirus. *Methods Mol Biol.* 2003; 215:235–246. https://doi.org/10.1385/1-59259-345-3:235 PMID: 12512303

33. Steinert AF, Proffen B, Kunz M, et al. Hypertrophy is induced during the in vitro chondrogenic differentiation of human mesenchymal stem cells by bone morphogenetic protein-2 and bone morphogenetic protein-4 gene transfer. *Arthritis research & therapy.* 2009; 11(5):R148.

34. Noth U, Tuli R, Osyczka AM, Danielson KG, Tuan RS. In vitro engineered cartilage constructs produced by press-coating biodegradable polymer with human mesenchymal stem cells. *Tissue engineering.* 2002; 8(1):131–144. https://doi.org/10.1089/107632702753503126 PMID: 11886661

35. Sharma P, Kumar P, Sharma R, Bhatt GD, Dhot PS. Tissue Engineering; Current Status & Futuristic Scope. *Journal of medicine and life.* 2018; 32(6):1289–1300. https://doi.org/10.25122/jml-2019-0032 PMID: 31666821

36. Zylinska B, Silmanowicz P, Sobczynska-Rak A, Jarosz L, Szponder T. Treatment of Articular Cartilage Defects: Focus on Tissue Engineering. *In vivo (Athens, Greece).* 2018; 32(6):1289–1300.

37. Jiang X, Huang X, Jiang T, Zheng L, Zhao J, Zhang X. The role of Sox9 in collagen hydrogel-mediated chondrogenic differentiation of adult mesenchymal stem cells (MSCs). *Biomaterials science.* 2018; 6(6):1556–1568. https://doi.org/10.1039/c8bm00317c PMID: 29696285
38. Kupcsik L, Stoddart MJ, Li Z, Benneker LM, Alini M. Improving chondrogenesis: potential and limitations of SOX9 gene transfer and mechanical stimulation for cartilage tissue engineering. *Tissue Eng Part A*. 2010; 16(6):1845–1855. https://doi.org/10.1089/ten.TEA.2009.0531 PMID: 20067399

39. Takahashi T, Ogasawara T, Asawa Y, et al. Three-dimensional microenvironments retain chondrocyte phenotypes during proliferation culture. *Tissue engineering*. 2007; 13(7):1583–1592. https://doi.org/10.1089/ten.2006.0322 PMID: 17630901

40. Kino-Oka M, Yashiki S, Ota Y, et al. Subculture of chondrocytes on a collagen type I-coated substrate with suppressed cellular dedifferentiation. *Tissue engineering*. 2005; 11(3–4):597–608. https://doi.org/10.1089/ten.2005.11.597 PMID: 15869436

41. Mennan C, Garcia J, McCarthy H, et al. Human Articular Chondrocytes Retain Their Phenotype in Sustained Hypoxia While Normoxia Promotes Their Immunomodulatory Potential. *Cartilage*. 2019; 10(4):467–479. https://doi.org/10.1177/1947603518769714 PMID: 31992984

42. He CX, Zhang TY, Miao PH, et al. TGF-β1 gene-engineered mesenchymal stem cells induce rat cartilage regeneration using nonviral gene vector. *Biotechnol Appl Biochem*. 2012; 59(3):163–169. https://doi.org/10.1002/bab.1001 PMID: 23586825

43. Stellavato A, Tirino V, de Novellis F, et al. Biotechnological Chondroitin a Novel Glicosaminoglycan With Remarkable Biological Function on Human Primary Chondrocytes. *Journal of cellular biochemistry*. 2016; 117(9):2158–2169. https://doi.org/10.1002/jcb.25556 PMID: 27018169

44. Mesure B, Menu P, Venkatesan JK, Cucchiarini M, Velot É. Biomaterials and Gene Therapy: A Smart Combination for MSC Musculoskeletal Engineering. *Current stem cell research & therapy*. 2019; 14(4):337–343.

45. Izadifar Z, Chen X, Kulyk W. Strategic design and fabrication of engineered scaffolds for articular cartilage repair. *Journal of functional biomaterials*. 2012; 3(4):799–838. https://doi.org/10.3390/jfb3040799 PMID: 24955748

46. Dickhut A, Dexheimer V, Martin K, Lauinger R, Heisel C, Richter W. Chondrogenesis of human mesenchymal stem cells by local transforming growth factor-beta delivery in a biphasic resorbable carrier. *Tissue Eng Part A*. 2010; 16(2):453–464. https://doi.org/10.1089/ten.TEA.2009.0168 PMID: 19705961